RUNX3 and anaplastic large cell lymphoma: We and others demonstrated that RUNX3 is oncogenic and its overexpression is correlated with poor prognosis and drug resistance in NKTL and anaplastic large cell lymphoma (ALCL) [17, 79, 80].